SBI Securities Co. Ltd. Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

SBI Securities Co. Ltd. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 49,273 shares of the company's stock, valued at approximately $333,000.

A number of other hedge funds also recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth $25,000. Decker Retirement Planning Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after purchasing an additional 4,091 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $8.25.

Remove Ads

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded up $0.35 during midday trading on Friday, reaching $6.59. The stock had a trading volume of 19,150,247 shares, compared to its average volume of 25,833,668. The firm's 50-day moving average price is $7.64 and its 200 day moving average price is $7.07. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The firm has a market capitalization of $2.57 billion, a PE ratio of -4.31 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same period in the previous year, the company posted ($0.42) earnings per share. The company's quarterly revenue was down 57.8% compared to the same quarter last year. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.